NeOnc Technologies Holdings press releases

Artificial intelligence is helping scientists investigate treatments and connect medical knowledge. $NTHI, $AZN, $BMY, and $GENB

Houston, Texas--(Newsfile Corp. - October 21, 2026) - As NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) prepares for an upcoming FDA meeting, its work in Abu Dhabi is bringing that human side of bio…

NeOnc (NASDAQ:NTHI) just reported impressive Compassionate Care program results and is heading into catalyst season

Houston, Texas--(Newsfile Corp. - October 16, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is confronting one of the most consequential tests of its investigational brain-cancer platform as it p…

NeOnc (NASDAQ: NTHI) reported significant improvement in a critically ill 3-year-old boy with an aggressive brain tumor after receiving NEO100

NeOnc (NASDAQ: NTHI) made a powerful leadership move at a pivotal moment in its brain-cancer drug development strategy

NeOnc’s (NASDAQ: NTHI) investigational brain-cancer programs, NEO100 and NEO212, have upcoming FDA catalysts

NeOnc (NASDAQ: NTHI) is heading toward another potentially important regulatory milestone, with upcoming FDA meeting

NeOnc (NASDAQ: NTHI) is scheduled to meet with the FDA for an in-person End-of-Phase 1 Type B meeting covering its experimental brain-cancer drug NEO212.

NeOnc (NASDAQ: NTHI) picks up fresh Wall Street coverage, at a pivotal moment, with a Buy rating and $20 price target

NeOnc (NASDAQ: NTHI) is becoming a prominent player, as brain cancer research is entering an increasingly sophisticated era.

NeOnc's (NASDAQ: NTHI) NEO100 is testing a different answer to one of brain cancer’s oldest problems.

NeOnc (NASDAQ: NTHI) removed a significant overhang from its capital structure, with zero common shares issued in the process.

NeOnc NASDAQ: NTHI) executives have made approximately $629,000 in insider buys since announcing its Phase 2a results on August 12.

NeOnc’s (NASDAQ:NTHI) CEO purchased another 37,000 shares of the company’s common stock, following a $15 financing with healthcare-focused institutions

NeOnc’s (NASDAQ: NTHI) CEO continues insider buying, sending investors a signal that is impossible to ignore.

NeOnc (NASDAQ:NTHI) announced a $15 million registered direct offering priced at-the-market